Sanara MedTech Inc. (SMTI) · Oct 29, 2026 · Disposition

Sanara MedTech disposition sells THP for $2M, sharpens surgical focus

$2M disposition — Approximately $2.0M purchase price plus earnout rights

Sanara MedTech’s disposition sells Tissue Health Plus assets for about $2M, advancing its exit from the non-core platform and surgical refocus.

Sanara is refocusing on a pure-play surgical solutions business after moving away from Tissue Health Plus and its value-based wound-care platform.

The strategic exit is now executed, not just planned. Sanara sold all THP assets—including its business software products and related intellectual property—on October 6, 2026. That turns the previously known wind-down into a completed disposition and removes a non-core operating distraction. The direction was already visible in the company’s prior disclosures, so the surprise is mainly the transaction detail rather than the strategic decision.

The financial benefit is modest but tangible. The company received approximately $2.0 million and retained certain earnout rights. The filing does not disclose the assets’ carrying value, expected earnout amount, use of proceeds, or whether the sale produces a gain or loss, so the cash impact cannot be judged beyond the headline proceeds.

Bottom line: This is a small, partly anticipated cleanup transaction that advances Sanara’s surgical refocus. It matters more for simplifying the business than for the immediate $2 million of proceeds.

Original filing on SEC EDGAR

More Sanara MedTech Inc. news

Sanara MedTech disposition sells THP for $2M, sharpens surgical focus | SMTI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.